

Special Issue

Influenza Virus Neuraminidase: Structure, Evolution and Therapeutics

Message from the Guest Editors

This Special Issue, entitled “Influenza Virus Neuraminidase: Structure, Evolution, and Therapeutics”, aims to present recent research on several aspects of influenza neuraminidase (NA). Some of its focal points include, but are not limited to, the following:

- Protein structure;
- Genetic evolutionary changes and pathways;
- Selective pressure;
- Targeted antivirals: licensed and novel approaches/inhibitors;
- Antiviral resistance and reduced susceptibility;
- NA-based monoclonal antibodies;
- NA as a vaccine antigen.

Reviews, original research articles, brief reports, and communications from academia, research institutes, or industries are welcome.

Guest Editors

Dr. Helena Rebelo-De-Andrade

Antiviral Resistance Lab, Research & Development Unit, Infectious Diseases Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

Dr. Vanessa Correia

Antiviral Resistance Lab, Research & Development Unit, Infectious Diseases Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

Deadline for manuscript submissions

closed (20 December 2024)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.6
Indexed in PubMed



mdpi.com/si/202255

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.6
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2026).